Company Overview and News

3
PM Modi#39;s 4 years in office: A few hits and misses D-Street is talking about

2018-05-27 moneycontrol
Equity benchmarks in the four years of Modi government being in power had a good run. The Sensex and Nifty, between May 26, 2014 and May 25, 2018 managed to surge around 44-45 percent.
532960 511605 IBVENTURES ARIHCAPM IDBLZ

1
SBI shares continue to gain, up nearly 4%

2018-05-23 moneycontrol
Shares of State Bank of India (SBI) extended its gaining streak for the second straight session today, rising nearly 4 percent, amid positive guidance by the company. The stock gained 3.56 percent to end at Rs 263.20 on BSE. During the day, it surged 6.11 percent to Rs 269.70.
511605 ARIHCAPM SBAZ

41
Market Live: Sensex under pressure; TCS rebounds; Cipla, Grasim top gainers

2018-04-16 moneycontrol - 1
12:10 pm Order Win: SPML Infra Limited with its joint venture partner OM Metals Infraprojects has secured an international order from Ministry of Food and Agriculture, Republic of Ghana for the work related to rehabilitation and completion of Kpong left bank irrigation project in Ghana, Africa for USD 32 million (approximately Rs 205 crore).
SPMLINFRA 513262 500325 500402 RELIANCE TCHQY 532755 532215 511288 5225 532187 OMMETALS AXISBANK RIGD ARIHCAPM DCBBANK HDFCBANK 531092 500570 IHHHF TATAMOTORS RLNIY GRUH AXB INDUSINDBK IBN 532505 GRHFY 532843 BHEL TECHM AXBKY AXBA 532772 ICICIBANK FORTIS 511605 HDB 532174 500180 BRHTY 500103 UCOBANK Q0F SSWL TTM

 
Global markets end in green despite trade war, Syria tensions; US markets rise as Dow up 1.7%

2018-04-15 moneycontrol
Positive momentum in the market continued for the seventh consecutive session on Friday, helping benchmark indices post a healthy performance for the third week in a row.
511605 ARIHCAPM

57
Market Live: Sensex drops 500 pts, Midcap dips 2%; IT rebounds, Asia down 3-5%

2018-03-23 moneycontrol
11:58 am US Spending Bill: The US Senate passed a USD 1.3 trillion federal spending bill in dramatic dark-of-night fashion early today, overcoming hurdles that threatened to send the government into its third shutdown of 2018.
500325 BHUSANSTL 532712 533179 532754 RCOM 532483 MS 500570 9696 500055 RLNIY ASHOKLEY AXB APOLLOTYRE YYBKY AYRQY AKLD CNRYY AXBA TATASTEEL TATLY 500180 CANBK AKLS RELIANCE GMQRY GMRINFRA 532215 500470 AXISBANK RIGD ARIHCAPM HDFCBANK 500477 TATAMOTORS YESBANK UBNC 500877 IBN 532648 AXBKY ICICIBANK TTST 511605 HDB 532174 PERSISTENT TTM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...